[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pleural-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pleural-infections":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100644204","phase-3-comparison-of-early-pleural-irrigation-strategy-with-saline-to-the-standard-of-care-for-the-management-of-complicated-pleural-infections-100644204",false,"NCT07666464","Comparison of Early Pleural Irrigation Strategy With Saline to the Standard of Care for the Management of Complicated Pleural Infections.","Randomized Controlled Trial Comparing an Early Pleural Irrigation Strategy With Saline to the Standard of Care for the Management of Complicated Pleural Infections.","EPISSOC","Inclusion Criteria:\n\n* Adults (≥18 years old) capable of fully understanding the study;\n* Complicated pleural infection (macroscopically purulent fluid, positive for bacteria on Gram's staining, positive on culture for bacterial infection, loculated effusion, pH \\\u003C7.2, great abundance) leading to thoracic drainage;\n* Initial ultrasound evaluation to estimate pleural fluid abundance and detect fibrinous septation;\n* Social security affiliation\n* Written informed consent\n* Highly effective contraceptive methods for women of childbearing age include: Combined hormonal contraception (estrogen and progestogen) associated with inhibition of ovulation (oral, intravaginal, transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable); intrauterine device; hormone- releasing intrauterine system; bilateral occlusion of the Fallopian tubes; vasectomized partner; sexual abstinence\n\nExclusion Criteria:\n\n* Tuberculous pleural effusions;\n* Previous treatment with intrapleural fibrinolytic agents (urokinase, streptokinase, alteplase, or DNase) or intrapleural saline lavage;\n* Previous thoracic surgery for pleural infection;\n* Contraindications to auxiliary treatments, to fibrinolysis or surgery as well as to procedures such as drainage and lavage;\n* Pregnancy or lactation;\n* Expected survival of less than 3 months;\n* Thoracic drainage since more than 24h;\n* Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision);\n* Inability to give informed written consent;\n* Participation in another clinical trial;\n* Patient being a relative of the investigator or any member of the team directly involved in the study, including assistant physicians, pharmacists, nurses, and coordinators","ALL","18 Years",{"count":20,"type":21},244,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Intrapleural enzyme therapy (IET) is regarded by recent guidelines as a \"rescue\" therapy for managing complicated pleural infections; however, it is associated with significant side effects, including pleural bleeding, pain, and fever. Pleural irrigation with saline may serve as an alternative, yet evidence supporting its effectiveness is limited to a single small- scale, single-center randomized trial. The objective of the study is to compare the risk of treatment failure at 30 days (defined as a composite outcome that includes death, the need for thoracic surgery, or additional intrapleural enzyme therapy) between an early pleural irrigation strategy and standard care for complicated pleural infections.",[27,28],"Therapy","Pleural Infections",[30,31],"therapy","pleural infections","RECRUITING","2026-06-30",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":36},"2026-05-13",{"date":40,"type":21},"2029-08",{"name":42,"class":43},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":66,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100600274","phase-4-once-daily-intrapleural-enzyme-therapy-in-complicated-parapneumonic-effusion-or-empyema-100600274","NCT07095361","Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema","Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema (ONLY ONCE)","ONLY ONCE","Inclusion Criteria:\n\n* Written informed consent obtained from patient or patient's legally authorized representative (LAR) to participate in the study and HIPAA authorization for release of personal health information.\n* Subject is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.\n* Age ≥ 18 years at the time of consent.\n* Patient is admitted to the hospital and with a pleural effusion that is drained with a small-bore chest tube or one that allows for administration of IET\n* Pleural fluid that is one of the following:\n\n  (i) Macroscopically purulent or pleural fluid gram stain or culture positive for bacteria (ii) potential of hydrogen (pH) \\\u003C 7.2 (iii) Pleural fluid glucose \\\u003C 60mg\u002FdL (iv) Pleural fluid Lactate Dehydrogenase (LDH) \\> 1,000 IU\u002FL\n* Patient is deemed a candidate to receive intrapleural enzyme therapy as defined by having a residual collection or persistent sepsis 24 hours after initial chest tube placement\n\nExclusion Criteria:\n\n* Known pregnancy or lactating females\n* Prisoners\n* Age \\\u003C18 years at time of consent\n* Previous treatment with intra-pleural fibrinolytic agents, DNase, or both during the same hospital admission\n* Known sensitivity or allergic reaction to DNAse or tPA\n* Coincidental stroke, major hemorrhage (requiring blood transfusions within the last 5 days), major trauma, or major surgery within the last 5 days\n* Previous pneumonectomy or active bronchopleural fistula on the affected side\n* Therapeutic systemic anticoagulation or antiplatelet agents that cannot held for more than 48 hours prior to IET administration\n* Expected survival of less than 3 months due to a pathologic condition other than that causing the pleural infection",{"count":54,"type":21},270,[56],"PHASE4","The goal of this clinical trial is to find out if giving certain medications once a day works just as well as giving them twice a day to treat infections around the lungs (called pleural infections). These medications-tissue plasminogen activator (tPA) and deoxyribonuclease (DNase)-are placed through a chest tube into the space between the lung and the chest wall to help clear out the infection.\n\nThe investigators are trying to learn:\n\n* Does using the medicine once a day work just as well as using it twice a day?\n* Are there any differences in outcomes between patients who get the medicine once a day versus twice a day?\n* Does more or less fluid remain in the chest (seen on a chest x-ray) depending on how often the medicine is given?\n\nParticipants will:\n\n* Have an infection around their lung and will already be getting normal hospital care, including a chest tube to drain the infected fluid around their lung.\n* Be asked to give permission to join the study.\n* Be randomly chosen (like flipping a coin) to get the medications either once a day or twice a day through the chest tube.",[59,28,60,61,62,63,64,65],"Pleural Infection Bacterial","Pleural Infections and Inflammations","Empyema, Pleural","Empyema","Complicated Pleural Effusion\u002F Empyema","Pleural Effusion Associated With Pulmonary Infection","Pleural Effusion",[67,68,69,70],"Lytics","Intrapleural enzyme therapy","Once daily","lytic therapy","2026-05-14",{"date":73,"type":36},"2026-05-19",{"date":75,"type":36},"2025-09-11",{"date":77,"type":21},"2028-09-30",{"name":79,"class":43},"University of North Carolina, Chapel Hill",6,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100635272","role-of-medical-thoracoscopy-in-pleural-infection-prompt-trial-100635272","NCT07550530","Role of Medical Thoracoscopy in Pleural Infection (PROMPT Trial)","Multicentre Prospective Comparative Study of Medical Thoracoscopy vs Standard of Care in the Management of Pleural Infection","PROMPT","Inclusion criteria\n\n* Adults ≥ 18 years\n* Clinical and radiological diagnosis of pleural infection (purulent, culture-positive, or pH \\\u003C 7.2)\n* Need of pleural drainage\n* Able and willing to give informed consent\n\nExclusion criteria\n\n* Chest drain in situ \\>24h before randomisation\n* Post-traumatic pleural effusion\n* Known allergy to fibrinolytic agents or contraindication to thoracoscopy\n* Pregnancy or breastfeeding\n* Life expectancy \\\u003C 3 months from another illness\n* Previous lung surgery (pneumonectomy) in the same side of pleural infection\n* Previous pleurodesis in the same side of pleural infection\n* Any contraindication to Medical thoracoscopy",{"count":90,"type":21},170,[92],"NA","The PROMPT study is testing whether an early keyhole procedure called Medical Thoracoscopy, which lets doctors look inside the chest and remove infected fluid, works better than current standard treatment (medicines to break up thick fluid) for people with pleural infection. About 170 patients in several hospitals will be randomly assigned to one of the two treatments, and researchers will see which approach results in fewer additional procedures-such as another drain or surgery-within 30 days, as well as how quickly people recover and whether they experience any complications. Everyone in the study receives high-quality care, and the results will help doctors better understand which treatment gives patients the best chance of recovering quickly and safely",[95,28,60],"Pleural Infection",[97,98,99],"Pleural infection","Medical Thoracoscopy","Trial","NOT_YET_RECRUITING","2026-04-21",{"date":103,"type":36},"2026-04-24",{"date":105,"type":21},"2026-11-01",{"date":107,"type":21},"2029-03-31",{"name":109,"class":43},"Università Politecnica delle Marche"]